makesumgravy
15 years ago
SenoRx Reports Record Gross Margin in First Quarter 2009 On Revenue Growth of 20.5 Percent
Press Release
Source: SenoRx, Inc.
On Wednesday May 6, 2009, 4:15 pm EDT
Buzz up! 0 Print
Companies:SenoRx, Inc.
IRVINE, Calif., May 6, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO - News) today reported financial results for its first quarter ended March 31, 2009. Revenue for the quarter increased 20.5 percent to $12.9 million, compared with $10.7 million in the first quarter a year ago. Gross profit increased 36.6 percent to $9.1 million, or a record 70.3 percent of revenue, up from $6.6 million, or 62.1 percent of revenue, in the first quarter of 2008.
SenoRx reported a significantly reduced operating loss for the first quarter of $879,000, a decline of 60.6 percent compared with $2.2 million in the same period last year. The operating loss for the quarter included stock-based compensation expense of $675,000, compared with $554,000 in the first quarter of 2008. Also included in the results for the first quarter were attorney and related costs incurred as a result of ongoing patent litigation with Hologic of $264,000 compared with $765,000 in the first quarter last year.
Interest expense for the first quarter increased to $57,000, compared to $24,000 a year ago. Interest income decreased to $8,000 compared to $259,000 from the first quarter of 2008, due to lower average cash balances and lower interest rates. Cash balances were lower during the quarter compared with a year ago due to continued usage of our cash to fund operations and patent litigation.
Net loss for the first quarter of 2009 was $928,000 or 5 cents per share, compared with $2.0 million or 12 cents per share in the same period last year. Excluding patent litigation and non-cash charges for stock-based compensation, net income was $10,000 for the quarter compared to a net loss of $675,000 for the same period last year.
Lloyd Malchow, SenoRx President and Chief Executive Officer, said, "Despite the challenging global economic environment, our first quarter results continued to post encouraging growth in both revenues and gross margin. Therapuetic disposable revenues continued its strong growth trend, increasing to $2.9 million compared with $617,000 in the first quarter a year ago, when we began the full commercial launch of our Contura MLB, and increased 35.3 percent sequentially over the fourth quarter of 2008. Revenue from biopsy disposables increased 13.5 percent to $5.5 million, as the installed base of EnCor systems continued to grow to 814 from 594 in the first quarter a year ago and from 776 at the end of 2008. As we expected, biopsy capital equipment revenues softened, posting a 35.1 percent decrease to $825,000 from $1.3 million in the first quarter last year, largely reflecting global credit and currency issues that are impacting capital purchases both in the U.S. and around the world."
Malchow continued, "While revenues in total were impacted by global economic issues, this was offset by strong growth in our product gross margin which was ahead of our expectations. Gross margin in the first quarter was a record 70.3 percent, compared with 62.1 percent in the first quarter last year, and 69.1 percent in the fourth quarter of 2008. The increase primarily reflects improvement in the sales mix due to a growing contribution from higher-margined Contura MLB sales, along with increasing operating leverage on our manufacturing overhead, stemming from increased sales volume and inventory unit production."
SenoRx finished the quarter in a solid financial position with cash and cash equivalents of $15.0 million and minimal debt. SenoRx continues to maintain a credit facility that allows it to borrow up to $10.0 million tied to growth in receivables and inventories, of which $7.6 million was available for advance as of March 31, 2009. Cash flow during the quarter, including litigation expense, was essentially neutral, and the company did not draw upon this line of credit.
2009 Outlook
If economic conditions continue to impact capital equipment revenues, SenoRx expects it could be more challenging to achieve the top of its projected revenue range. However, the company believes that modestly lower revenues could be offset by encouraging trends in expected gross margin, resulting in no material change in gross profit. As a result, SenoRx is making no change at this time to its estimate that revenues for 2009 will be in a range of $56 to $59 million, with product gross margin expected to be at least 68 percent. SenoRx continues to believe it will be cash flow positive for the year, excluding patent litigation expenses.
In addition, SenoRx continues to estimate that deferred compensation and equity-based compensation expense will range between $2.4 million and $2.8 million for 2009. These ranges could be materially impacted based upon the number of options granted and fluctuation in the market price of the company's common stock.
With regard to the Hologic matter, a ruling was issued on February 18, 2009 relating to the Markman claims construction hearing. We are waiting for a response from the Court to a joint stipulation, which was filed by both parties on April 14, 2009, requesting the Court allow summary judgment briefing and argument as to certain validity and infringement issues. While it remains difficult to forecast patent litigation expense for the full year, SenoRx estimates that patent litigation costs in the second quarter of 2009 will range between $450,000 and $600,000.
makesumgravy
15 years ago
Securities Registration: Employee Benefit Plan (S-8)
Date : 03/16/2009 @ 3:14PM
Source : Edgar (US Regulatory)
Stock : (SENO)
Quote : 3.84 0.09 (2.40%) @ 7:55PM
- Securities Registration: Employee Benefit Plan (S-8)
As filed with the Securities and Exchange Commission on March 16, 2009
Registration No.
333-______
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
--------------------------------------------------------------------------------
SENORX, INC.
(Exact name of Registrant as specified in its charter)
--------------------------------------------------------------------------------
Delaware 33-0787406
(State or other jurisdiction of
incorporation or organization) (I.R.S.
Employer
Identification Number)
3 Morgan
Irvine, CA 92618
(949) 362-4800
(Address including zip code, and telephone number, including area code, of principal executive offices)
--------------------------------------------------------------------------------
2006 EQUITY INCENTIVE PLAN
(Full title of the plan)
--------------------------------------------------------------------------------
Lloyd H. Malchow
President and Chief Executive Officer
SenoRx, Inc.
3 Morgan
Irvine, CA 92618
(949) 362-4800
(Name, address, and telephone number, including area code, of agent for service)
--------------------------------------------------------------------------------
Copy to:
Elton Satusky, Esq.
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CALCULATION OF REGISTRATION FEE
Title of
Securities
to be
Registered Maximum
Amount
to be
Registered (1) Proposed
Maximum
Offering
Price Per
Share Proposed
Maximum
Aggregate
Offering
Price Amount of
Registration
Fee
Common Stock
$0.001 par value per share 618,551 shares (2) $ 2.78 (3) $1,719,571.78 $95.96
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional shares of common stock of SenoRx, Inc. (the “Registrant”) that become issuable under its 2006 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that results in an increase in the number of the Registrant’s outstanding shares of common stock.
(2) This total represents (i) the additional shares approved by the Registrant’s board of directors for issuance under the 2006 Equity Incentive Plan, and (ii) additional shares issuable under the 2006 Equity Incentive Plan upon the cancellation and return of outstanding stock options under the Registrant’s 1998 Stock Plan, which shares were not registered under the Registration Statements on Form S-8, as such were filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2007 and March 3, 2008, respectively.
(3) Estimated in accordance with paragraphs (c) and (h) of Rule 457 solely for the purpose of calculating the total registration fee. Computation based upon the average of the high and low prices of the common stock as reported on the NASDAQ Global Market on March 10, 2009.
--------------------------------------------------------------------------------
INCORPORATION OF PREVIOUS REGISTRATION STATEMENTS
SenoRx, Inc. (the “Registrant”) previously filed Registration Statements on Form S-8 with the SEC on April 2, 2007 and March 3, 2008 (File Nos. 333-141818 and 333-149498, respectively) in connection with its 2006 Equity Incentive Plan (the “Prior Registration Statements”). This Registration Statement on Form S-8 is filed to register an additional 618,551 shares of common stock under the Registrant’s 2006 Equity Incentive Plan. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements relating to the 2006 Equity Incentive Plan are incorporated by reference into this Registration Statement to the extent not replaced hereby.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference .
There are hereby incorporated by reference in this Registration Statement the following documents and information heretofore filed by the Registrant with the SEC:
(1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as filed with the SEC on March 16, 2009 pursuant to Section 13 of the Securities Act of 1934, as amended (the “Exchange Act”); and
(2) The description of the Registrant’s common stock shares contained in the Registration Statement on Form 8-A filed pursuant to Section 12(b) of the Exchange Act, declared effective on March 28, 2007, including any amendment or report filed for the purpose of updating such description.
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.
Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities .
Not applicable.
Item 5. Interests of Named Experts and Counsel .
Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich & Rosati, P.C. own an interest representing less than 1% of the Registrant’s outstanding common stock.
II-1
--------------------------------------------------------------------------------
Item 6. Indemnification of Directors and Officers .
Section 145(a) of the Delaware General Corporation Law provides in relevant part that “[a] corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.” With respect to derivative actions, Section 145(b) of the Delaware General Corporation Law provides in relevant part that “[a] corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor . . . [by reason of such person’s service in one of the capacities specified in the preceding sentence] against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.”
The Registrant’s Certificate of Incorporation and Bylaws as currently in effect provide that the Registrant shall indemnify its directors and officers to the fullest extent permitted under the Delaware General Corporation Law, except that the Registrant will not be required to indemnify such person if the indemnification sought is in connection with a proceeding initiated by such person without the authorization of the board of directors. As permitted by the Registrant’s Bylaws, the Registrant has obtained insurance on behalf of its directors and officers against liability arising out of his or her actions in such capacity, regardless of whether the Registrant has the power to indemnify such individual against such liability under the provisions of the Delaware General Corporation Law.
The Registrant has entered into, and intends to enter into in the future, indemnification agreements with each of its directors and executive officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law, subject to certain exceptions, as well as certain additional procedural protections.
The Amended and Restated Investors’ Rights Agreement dated May 5, 2006, as amended (the “Rights Agreement”), between the Registrant and certain investors provides for indemnification of the Registrant’s directors and officers in connection with registration of the Registrant’s common stock under the Rights Agreement.
The indemnification provision in the Registrant’s Certificate of Incorporation, Bylaws and Rights Agreement and the indemnification agreements entered into between the Registrant and the Registrant’s directors and executive officers, may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities arising under the Securities Act.
See also the Registrant’s undertakings under Item 9 of this Registration Statement.
Item 7. Exemption from Registration Claimed .
Not applicable.
Item 8. Exhibits .
Exhibit
Number Description
4.1 Registrant’s Registration Statement No. 001-33382 on Form 8-A, incorporated by reference pursuant to Item 3(4) of this Registration Statement.
4.2* Amended and Restated Certificate of Incorporation of the Registrant as filed with the Secretary of State of Delaware on April 2, 2007.
4.3* Amended and Restated Bylaws of the Registrant.
5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.
23.1 Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.2 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (see Exhibit 5.1).
24.1 Power of Attorney (see page II-4).
99.1** 2006 Equity Incentive Plan, as amended and restated on February 26, 2009.
* Incorporated by reference to exhibits filed with the Registration Statement on Form S-1, as amended (Registration No. 333-134466), as declared effective on March 28, 2007.
** Incorporated by reference to the exhibit filed with the Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as filed with the SEC on March 16, 2009.
II-2
--------------------------------------------------------------------------------
Item 9. Undertakings .
A. We hereby undertake:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
Provided, however, that paragraphs (i) and (ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by us pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
B. We hereby undertake that, for purposes of determining any liability under the Securities Act, each filing of our annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to applicable law, our Amended and Restated Certificate of Incorporation, Bylaws, Rights Agreements or indemnification agreements, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
II-3
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on this 16 th day of March, 2009.
SENORX, INC.
By: /s/ Lloyd H.
Malchow
Lloyd H. Malchow, President and Chief Executive
Officer (Principal Executive Officer)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lloyd H. Malchow and Kevin J. Cousins, jointly and severally, as his attorneys-in-fact, with full power of substitution in each, for him in any and all capacities to sign any amendments to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
Signature Title Date
/s/ Lloyd H. Malchow
--------------------------------------------------------------------------------
Lloyd H.
Malchow
President, Chief Executive Officer and Director (Principal Executive Officer) March 16, 2009
/s/ Kevin J. Cousins
--------------------------------------------------------------------------------
Kevin J. Cousins Chief Financial Officer and Vice President, Finance (Principal Accounting Officer) March 16, 2009
/s/ Thomas A. Bender
--------------------------------------------------------------------------------
Thomas A. Bender Director March 16, 2009
/s/ Kim D. Blickenstaff
--------------------------------------------------------------------------------
Kim D. Blickenstaff Director March 16, 2009
/s/ Vickie L. Capps
--------------------------------------------------------------------------------
Vickie L. Capps Director March 16, 2009
/s/ Frederick J. Dotzler
--------------------------------------------------------------------------------
Frederick J.
Dotzler
Director March 16, 2009
/s/ John L. Erb
--------------------------------------------------------------------------------
John L. Erb Director March 16, 2009
/s/ Gregory D. Waller
--------------------------------------------------------------------------------
Gregory D. Waller Director March 16, 2009
II-4
--------------------------------------------------------------------------------
INDEX TO EXHIBITS
Exhibit
Number Description
4.1 Registrant’s Registration Statement No. 001-33382 on Form 8-A, incorporated by reference pursuant to Item 3(4) of this Registration Statement.
4.2* Amended and Restated Certificate of Incorporation of the Registrant as filed with the Secretary of State of Delaware on April 2, 2007.
4.3* Amended and Restated Bylaws of the Registrant.
5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.
23.1 Consent of Deloitte & Touch LLP, Independent Registered Public Accounting Firm.
23.2 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (see Exhibit 5.1).
24.1 Power of Attorney (see page II-4).
99.1** 2006 Equity Incentive Plan.
____________
* Incorporated by reference to exhibits filed with the Registration Statement on Form S-1, as amended (Registration No. 333-134466), as declared effective on March 28, 2007.
** Incorporated by reference to the exhibit filed with the Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as filed with the SEC on March 16, 2009.
II-5
News
Market Data
Register to chat with like-minded investors on our interactive forums.
surf1944
15 years ago
